Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 13/20 | 0.71 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.40 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylenediamine SCHEMBL11775933 | 0.88 | ERN1 (0.85) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL29375374 | 0.84 | ERN1 (1.00) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL294757 | 0.84 | ERN1 (1.00) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL8958081 | 0.82 | ERN1 (0.96) | ERN1TLR2TLR1TLR6TRIM24 | |
| Ethylene SCHEMBL11602187 | 0.79 | ERN1 (0.88) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL11802500 | 0.79 | ERN1 (0.58) | ERN1TLR2TLR1TLR6MCL1 | |
| SCHEMBL4325918 | 0.78 | ERN1 (0.56) | ERN1TLR2TLR1TLR6MCL1 | |
| SCHEMBL11775930 | 0.76 | ERN1 (0.81) | ERN1TLR2TLR1TLR6TRIM24 | |
| SCHEMBL28048788 | 0.72 | ERN1 (0.69) | ERN1TLR2TLR1TLR6CYP1A2 | |
| Salicyladehyde SCHEMBL10428031 | 0.71 | TRIM24 (0.58) | ERN1TRIM24TRIM33TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090311230-A1 | SYNTHETIC CATALYTIC FREE RADICAL SCAVENGERS USEFUL AS ANTIOXIDANTS FOR PREVENTION AND THERAPY OF DISEASE | MALFROY-CAMINE BERNARD | 2009-12-17 | — | — | US | disclosed |
| US-7582786-B2 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | EUKARION INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060149089-A1 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | EUKARION, INC. | 2006-07-06 | — | — | US | disclosed |
| US-6573257-B2 | Salen-metal complexes having superoxide, catalase and/or peroxidase activity to treat or prevent diseases from cell or tissue damage | EUKARION, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20020002157-A1 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | EUKARION, INC. | 2002-01-03 | — | — | US | disclosed |
| US-6046188-A | COMPOSITIONS OF SALEN-METAL COMPLEXES FOR ADMINISTRATION TO TREAT OR PREVENT DISEASES ASSOCIATED WITH CELL OR TISSUE DAMAGE PRODUCED BY FREE RADICALS SUCH AS SUPEROXIDE, AND COSMETIC AND FREE RADICAL QUENCHING FORMULATIONS | EUKARION, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5834509-A | SALEN-MANGANESE COMPLEXES | EUKARION, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| US-5696109-A | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | EUKARION, INC. (US) | 1997-12-09 | — | — | US | disclosed |
| WO-1996040149-A1 | SYNTHETIC CATALYTIC FREE RADICAL SCAVENGERS USEFUL AS ANTIOXIDANTS FOR PREVENTION AND THERAPY OF DISEASE | EUKARION, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002157-A1 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | CAT, SOD1, SOD3 | ERN1 4295/4885TLR2 4145/4885TLR1 3336/4885 |
| US-20090311230-A1 | SYNTHETIC CATALYTIC FREE RADICAL SCAVENGERS USEFUL AS ANTIOXIDANTS FOR PREVENTION AND THERAPY OF DISEASE | CAT, SOD1, SOD3 | ERN1 4295/4885TLR2 4145/4885TLR1 3336/4885 |
| US-20060149089-A1 | Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease | CAT, SOD1, SOD3 | ERN1 4295/4885TLR2 4145/4885TLR1 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.